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GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two 
classes of antidiabetic agents used in the management of diabetes based on incretin hormones. 
There is emerging evidence that they have anti-inflammatory effects.  Since most long-term 
complications of diabetes have a background of chronic inflammation, these agents may be 
beneficial against diabetic complications not only due to their hypoglycemic potentials but also 
via their anti-inflammatory effects. However, the exact molecular mechanisms by which GLP-
1RAs and DPP-4i exert their anti-inflammatory effects are not clearly understood. In this 
review, we discuss the potential molecular pathways by which these incretin-based therapies 
exert their anti-inflammatory effects.  
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The global prevalence of diabetes mellitus (DM) is rising rapidly (1). DM is a chronic disorder 
that carries considerable morbidity and mortality (2, 3). Chronic hyperglycemia due to DM 
triggers a cascade of pathophysiologic pathways such as oxidative stress, inflammation, 
apoptosis, necrosis, fibrosis, polyol pathway and hexosamine pathways leading to various 
diabetic complications (2, 4). Many classes of anti-diabetic medications have been developed 
for normalizing glycemia and prevent various complications of DM (5-7). The exact 
pathophysiology behind developing diabetes complications is not fully elucidated yet (2, 8), 
however, the inflammatory response has a considerable role in this (9-11).   
Glucagon-like peptide-1 (GLP-1) is a small peptide belonging to the family of incretin 
hormones predominantly secreted by the intestinal L-cells (as well as by neurons) which 
reduces blood glucose by stimulation of insulin release and inhibition of glucagon secretion 
(12). Based on the potent hypoglycemic effects of this peptide, two classes of antidiabetic 
medications have been developed. They are an agonist of GLP-1 receptors (GLP-1 receptor 
agonists) and inhibitors of enzyme metabolizing GLP-1 (as dipeptidyl peptidase-4 inhibitors 
or DPP-4i) (13-15). These antidiabetic medications have a lower risk of hypoglycemia and 
thereby, safely normalize the hyperglycemia to physiologic levels (16). Beyond their 
hypoglycemia effects, some evidence indicates that they have anti-inflammatory potentials and 
potentially have a protective effect against various diabetic complications by lowering the 
inflammatory response (17, 18). If so, they can be considered as therapeutic agents for the 
management of inflammation-dependent diabetic complications (18). In this study, we discuss 
the anti-inflammatory effects of GLP-1RA and DPP-4i which could potentially protect various 
tissues against diabetic complications.  
GLP-1 RA and DPP-4i  
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GLP-1RA is a class of antidiabetic agents that are approved by the FDA for the management 
of patients with diabetes (19). These medications reduce blood glucose in patients with diabetes 
by mimicking the effect of incretin hormones. Incretin hormones belong to a family of 
metabolic peptides including GLP-1 and GIP (gastric inhibitory peptide), which reduces 
postprandial glycemia by inhibition of glucagon secretion and stimulation of insulin release in 
a blood glucose-dependent manner (20-23). They can have additional physiologic effects such 
as delaying the gastric emptying, decreasing nutrient absorption, appetite suppression, 
improvement of lipid metabolism, inhibition of pancreatic β-cell apoptosis and induction of 
beta-cell neogenesis (24, 25, 22). GLP-1 specific receptors are predominantly located in the 
pancreatic β-cells and are of G-protein coupled receptors that increase cAMP (cyclic adenosine 
monophosphate) production resulting in cellular events leading to insulin secretion from the 
pancreatic β-cells (21, 26). DPP-4i are a class of antidiabetic medications that produce their 
hypoglycemic effects through GLP-1 by increasing its active circulating levels by inhibiting 
DPP-4, which is an enzyme that inactivates GLP-1 (27, 28). Therefore, the DPP-4i have similar 
but less potent hypoglycemic effects compared to GLP-1RA, although they are differences in 
their effects on body weight and risk of some adverse effects (28). 
 
Classes  Approved Forms Mechanisms of Action Ref. 
GLP-1ra 
Exenatide (Exendin-4), Liraglutide, 
Semaglutide, Dulaglutide, 
Lixisenatide, Albiglutide, 
Mimic glucose-lowering effects of the 
incretin-based hormones via glucagon 
suppression, insulin release, appetite 




Sitagliptin, Saxagliptin, Alogliptin, 
Linagliptin 
Increase the circulatory levels of active 
GLP-1 
(27, 28) 
Table 1; Two main classes of incretin-based diabetes medications   
 
Inflammatory hypothesis for the development of diabetic complications  
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Various inflammatory pathways are activated in patients with diabetes (9, 29). There is growing 
evidence that there is activation of inflammatory pathways in the pathophysiology of various 
diabetes complications such as diabetic retinopathy, diabetic nephropathy, diabetic neuropathy 
and cardiovascular disease (9, 29, 30, 10). In addition, higher levels of inflammatory cytokines 
are typically found in the plasma of patients with diabetic complications (29, 31).  
Figure 1; diabetes mellitus has bi-directional interaction with inflammatory mediators both of which 
intensify each other. This leads to inflammatory responses contributing to a higher risk for diabetic 
complications (TNF-α =tumor necrosis factor-alpha, IL=interleukin, MMPs=matrix 
metalloproteinase, MCP-1=monocyte chemoattractant protein-1, nf-κb=nuclear factor kappa b, TGF-
β=transforming growth factor-beta, ICAM-1=intercellular adhesion molecule 1, VCAM-1=vascular 
cell adhesion protein-1, ESAM=endothelial cell-selective adhesion molecule, MMP-2=matrix 
metalloproteinase-2, INF-γ=interferon gamma) 
Various inflammatory mediators such as TNF-α (tumor necrosis factor-alpha), IL (interleukin)-
1β, IL-6, IL-18, MMPs (matrix metalloproteinase), MCP-1 (monocyte chemoattractant 
protein-1), nf-κb (nuclear factor kappa b), TGF-β (transforming growth factor-beta), E-selectin, 
chemokines, different adhesion molecules as ICAM-1 (intercellular adhesion molecule 1) and 
VCAM-1 (vascular cell adhesion protein-1), TLRs (toll-like receptors), E-selectin, different 
adiponectin, endothelial cell-selective adhesion molecule (ESAM), MMP-2 (matrix 
metalloproteinase-2), MMP-9, and INF-γ (interferon-gamma) are involved in various forms of 
diabetic complications (figure 1) (32-34). These mediators are highly expressed and secreted 
in diabetic milieu resulting in the development of, an "inflammation hypothesis" which 
emphasizes the crucial role of inflammatory responses in the pathophysiology of diabetic 
complications (29, 35).  
Anti-inflammatory effects of GLP-1RA and DPP-4i  
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These agents can exert anti-inflammatory effects via several molecular mechanisms and 
signaling pathways (36, 37). In the following paragraphs, we review the potential mechanisms 
by which GLP-1RA and DPP-4i exert these anti-inflammatory effects (table 2).   
1. Glucotoxicity 
GLP-1RA and DPP-4i are commonly used in the management of type 2 diabetes and have 
potent hypoglycemic effects and thereby attenuate glucotoxicity which is typically observed in 
a diabetic milieu (38, 39). GLP-1 has multiple physiologic effects that enable it to optimize 
glucose metabolism and reverse glucotoxicity (40-42). Glucotoxicity is associated with a 
higher incidence of inflammatory responses (43). Glucose-induced inflammation is well 
recognized in the hyperglycemic milieu and is reported in several studies (44-46). Therefore, 
one can speculate that by lowering the glucotoxicity via improvement of glucose homeostasis 
can be potentially translated into lower inflammatory responses (47).  
Retnakaran and coworkers in 2014 reported that liraglutide (GLP-1RA) preserves beta-cell 
function by eliminating the glucotoxicity in patients with early T2DM (48). Also, Kong et al 
in 2014 reported that GLP-1 attenuated glucotoxicity by a mechanism dependent on RhoA-
ROCK (Rho-associated kinase) signaling pathway in beta cells (40). Moreover, Tremblay et al 
in 2014 provided direct evidence in a clinical study demonstrating that sitagliptin markedly 
decreases inflammatory markers such as CRP (C-reactive protein), IL-6, IL-18 and E-selecting 
in plasma of patients with T2DM (47). They demonstrated that the anti-inflammatory potential 
of sitagliptin is related to the improvement in glucose homeostasis (47). Although there is not 
enough direct evidence, intuitively, it is intuitive that eliminating the glucotoxicity via 
improvement in glucose homeostasis is one of the potential molecular mechanisms by which 
GLP-1RA and DPP-4i exert their anti-inflammatory effects.  
2. Recruitment of immune cells  
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Recruitment of different types of immune cells such as T lymphocytes, NK (natural killer) 
cells, B-lymphocytes, leucocytes and dendritic cells into the inflamed tissues is a well-known 
event during inflammatory responses (49-51). Therefore, suppressing these phenomena and 
lowering the infiltration by immune cells is one of the main mechanisms for attenuating the 
inflammatory responses in various tissues (50, 52). There is some evidence implying that GLP-
1RA and  DPP-4i can suppress or reduce the recruitment of immune cells (36, 37). Kodera and 
coworkers in 2011 found that exendin-4 ameliorates the inflammatory responses by preventing 
macrophage infiltration into the inflamed kidneys in diabetic rats (36). Also, Lee and 
colleagues in 2012 reported that GLP-1 reduced macrophage infiltration in adipocytes of obese 
mice (53). Moreover, Higashijima et al in 2015 demonstrated that DPP-4i (alogliptin) prevents 
the infiltration of CD68-macrophages into the kidneys in a non-diabetic milieu via GLP-1 
specific signaling pathways (37). Wang et al in 2014 provided further evidence implying that 
exendin-4 reduced inflammatory responses by suppressing macrophage infiltration in inflamed 
liver tissues (54). It has suggested that GLP-1 exerts these anti-inflammatory effects via 
reducing the chemoattractant factors such as IFN-𝛾-induced STAT1 (signal transducer and 
activator of transcription-1) which is essential for T-cell recruitment (55, 18). Therefore, 
suppressing the leukocyte infiltration towards the inflamed tissue is another possible pathway 
by which GLP-1RA and DPP-4i inhibit inflammatory responses.     
3. Nf-κb signaling pathway and cytokines' expression   
Nf-κb is a nuclear factor that is primarily recognized as a regulator of DNA expression but also 
plays essential roles in other cellular processes such as cell survival, response to external 
stimuli, synaptic plasticity and memory (56). It is a complex protein that regulates the 
transcription of various genes as well as inflammatory mediators and thereby, is responsible 
for immune responses and cytokine production in almost all types of human cells (57). 
Modulation of the nf-κb signaling pathway has been tried in different studies (58, 57). 
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Emerging data demonstrate that GLP-1 can modulate nf-κb activities (36, 59-62). GLP-1RA 
and DPP-4i can potentially reduce the nf-κb activity in inflamed tissues that in turn down-
regulates the expression of pro-cytokines (59-62).  
Lee and coworkers in 2012 found that GLP-1 reduced the nf-κb activation leading to lower 
cytokine production in the adipocytes of obese mice (53). Also, Kaidashev et al recently 
provided clinical evidence demonstrating that six weeks of liraglutide (GLP-1RA) therapy had 
an anti-inflammatory effect and reduced the expression of TNF-α, IkB,  TLR2, and  TLR4 via 
nf-κb inhibition in patients with T2DM (62). Furthermore, Nader and coworkers in 2018 
revealed that sitagliptin markedly reduces the nf-κb function in non-diabetic mice (61). El-
Sahar and coworkers in 2015 have shown that sitagliptin exerts its anti-inflammatory effects at 
least partly via nf-κb inhibition (60). This evidence strongly suggest that inhibition of nf-κb 
signaling pathways is another potential mechanism by which GLP-1 and DPP-4i provide anti-
inflammatory potentials in both diabetic and non-diabetic milieu. 
However, these anti-diabetic medications can also suppress the expression of cytokines via nf-
κb independent pathways (63). Velmurugan and coworkers in 2012 reported that exendin-4 
prevent cytokines' expression by a CREB (cAMP response element-binding protein) dependent 
mechanism in the pancreatic islets (63). Also, He et al in 2013 found that exendin-4 ameliorated 
the expression of inflammatory mediators by p38 MAPK (phospho‐mitogen activated protein 
kinase) pathways in CD4+ T cells (64). Moreover, Que and coworkers suggested that 
liraglutide (GLP-1RA) down-regulated the cytokines through the PKA/CREB pathway in rats 
(65). This evidence strongly suggests that GLP-1 can prevent the expression of cytokines not 
only via nf-κb modulation but also through other molecular mechanisms such as CREB and 
p38 MAPK pathways (63-65).                                                                                      
4. Oxidative stress 
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Oxidative stress is a common event in the diabetic milieu (66). This deleterious state induces 
other pathophysiologic pathways such as apoptosis, fibrosis, autophagy and inflammation (67). 
It has well confirmed that oxidative stress has dual interaction with inflammatory responses 
which both intensify others (67, 68). Thus, improvement in redox state translated to a lower 
incidence of inflammation (69, 68). GLP-1RA and DPP-4i can improve oxidative stress via 
several pathways such as nuclear factor erythroid 2-related factor 2 (nrf2) pathway, potentiation 
of antioxidant defense system, down-regulation of pro-oxidant enzymes such as NAD(P)H 
oxidase thereby lowering the free radical generation and improvement in glucose metabolism 
leading to lesser amount of toxic by-products such as AGEs (advanced glycation end-products) 
(70-72).  
There is strong evidence indicating that GLP-1RA and DPP-4i inhibit inflammatory responses 
through the re-adjustment of the redox state (73, 64, 60, 70, 74-76, 61). He et al in 2013 found 
that exendin‐4 ameliorates the inflammatory processes by lowering the oxidative stress in 
patients with diabetes (64). Also, Chen and coworkers in 2017 demonstrated that exendin-4 
can reduce inflammation via its antioxidative potentials in diabetic rats (74). Moreover, Chang 
and colleagues in 2017 reported that exendin-4 attenuates AGEs-induced inflammatory 
responses by its antioxidative effects in the mesangial cells of diabetic rats (70). Moustafa et al 
in 2018 provided further evidence indicating that anti-inflammatory potentials of liraglutide 
are at least partially related to its antioxidative effects (76). This evidence strongly suggests 
that GLP-1RA and DPP-4i can attenuate the inflammatory events via normalizing the redox 





Figure 2; GLP-1RA and DPP-4i suppress molecular pathways involved in diabetes-
induced inflammatory responses  
  
5. Lipotoxicity  
Lipotoxicity occurs when the excess byproducts of lipid metabolism accumulate in non-
adipose tissues which in turn, trigger a cascade of deleterious pathways such as apoptosis and 
inflammation (77). Some studies emphasized the role of lipotoxicity as a missing link between 
diabetes and various inflammatory disorders (77, 78). They suggested that lipotoxicity is the 
main cause of inflammatory processes in a diabetic milieu (79, 78). Thus, improving the lipid 
metabolism and correcting the plasma lipid profile can prevent or suppress inflammatory 
responses (80, 79, 81). There is some evidence confirming that GLP-1RA and DPP-4i have 
this effect (73, 82-84).  
Huang et al in 2015 found that intra-islet GLP-1 secretion is a potent intrinsic defense against 
lipotoxicity (82). They also reported that liraglutide can prevent lipotoxicity and in turn, 
inhibits the inflammatory response (82). Pastel and coworkers in 2016 illustrated that exendin-
4 ameliorates the inflammatory processes via improvement in lipid metabolism in cultured 
human adipocytes (83). Similarly, Ferreira and coworkers in 2010 found that can reduce 
inflammatory events through correcting the lipid metabolism in diabetic animals (73). Yin et 
al in 2016 demonstrated that exendin-4 attenuates lipotoxicity by correcting cholesterol 
homeostasis in the glomerular cells of diabetic mice (84). They also found that this effect was 
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accompanied by lowering the inflammatory responses in this tissue (84). More studies have 
reported the same results implying that GLP-1RA and DPP-4i prevent lipotoxicity in various 
tissues (85, 86). This evidence suggests that these classes of compounds can suppress 
inflammatory events through ameliorating lipotoxicity.  
 
Molecular Mechanisms Effects of GLP-1ra and/or DPP-4i  Ref. 
Glucotoxicity 
Eliminate glucotoxicity leading to a lower 
rate of glucose-induced inflammation  




Reduce leukocyte immigration toward the 




Directly down-regulate different 
inflammatory cytokines in several ways 
such as nf-κb inhibition  
(59-62) 
(55, 63, 64, 83, 
70, 74, 76, 87-
89, 62, 65) 
Lipotoxicity 
Correct lipid homeostasis leading to a lower 
rate of lipotoxicity-induced inflammation  
(73, 82, 83) 
Oxidative stress 
Improve redox state toward physiologic 
state leading to lower oxidative stress-
induced inflammation  
(73, 64, 60, 70, 
74-76, 61) 
Table 2; Possible molecular mechanisms by which GLP-1RA and DPP-4i exert their 





Treatment  Population of study  Mechanism of reducing inflammation   Ref.  
Exendin-4  Patients with T2DM  Normalize redox state    (64) 
Liraglutide Patients with T2DM Reduce the glucotoxicity  (48) 
Liraglutide Patients with T2DM 
Decline nf-κb dependent cytokines' 
expression  
(62) 
Sitagliptin  Patients with T2DM Reduce the glucotoxicity  (47) 
Sitagliptin Patients with T2DM 
Reduce the glucotoxicity, down-regulate 
inflammatory mediators   
(90) 
Sitagliptin Patients with T2DM 
Improve glucose homeostasis and thereby 
reduce glucotoxicity  
(47) 
Sitagliptin 
Patients with T2DM 
and cardiovascular 
diseases 
Normalize glucose homeostasis and reduce 
inflammatory cytokines  
(91) 
Table 3; Clinical studies on anti-inflammatory potentials of GLP-1RA and DPP-4i 
 
Conclusion 
GLP-1RA and DPP-4i are novel classes of anti-diabetic medications, in addition to their 
hypoglycemic effects can provide anti-inflammatory effects on various tissues. They can 
potentially prevent inflammatory events via at least five molecular mechanisms such as 
improvement in glucose homeostasis and lowering the glucotoxicity, normalizing the redox 
state and reducing the oxidative stress-induced inflammation, suppressing the leukocyte 
recruitment towards the inflamed tissue, reducing the lipotoxicity and down-regulation of 
various inflammatory mediators. These agents may be considered as potential therapeutic 
agents against various inflammatory disorders as well as diabetic complications.  
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